Insmed Inc (INSM)
67.03
+0.08
(+0.12%)
USD |
NASDAQ |
Jun 28, 16:00
66.99
-0.04
(-0.06%)
After-Hours: 20:00
Insmed SG&A Expense (TTM): 357.69M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 357.69M |
December 31, 2023 | 344.50M |
September 30, 2023 | 328.45M |
June 30, 2023 | 313.41M |
March 31, 2023 | 288.95M |
December 31, 2022 | 265.78M |
September 30, 2022 | 257.57M |
June 30, 2022 | 242.27M |
March 31, 2022 | 239.47M |
December 31, 2021 | 234.27M |
September 30, 2021 | 225.03M |
June 30, 2021 | 211.33M |
March 31, 2021 | 203.82M |
December 31, 2020 | 203.61M |
September 30, 2020 | 197.80M |
June 30, 2020 | 204.56M |
March 31, 2020 | 207.33M |
December 31, 2019 | 210.80M |
September 30, 2019 | 214.55M |
June 30, 2019 | 205.65M |
March 31, 2019 | 190.38M |
December 31, 2018 | 168.22M |
September 30, 2018 | 176.53M |
June 30, 2018 | 141.44M |
March 31, 2018 | 113.63M |
Date | Value |
---|---|
December 31, 2017 | 89.64M |
September 30, 2017 | 51.25M |
June 30, 2017 | 51.00M |
March 31, 2017 | 50.31M |
December 31, 2016 | 50.68M |
September 30, 2016 | 34.56M |
June 30, 2016 | 32.97M |
March 31, 2016 | 31.87M |
December 31, 2015 | 30.61M |
September 30, 2015 | 28.78M |
June 30, 2015 | 27.76M |
March 31, 2015 | 25.51M |
December 31, 2014 | 23.03M |
September 30, 2014 | 19.46M |
June 30, 2014 | 17.71M |
March 31, 2014 | 19.94M |
December 31, 2013 | 18.63M |
September 30, 2013 | 20.51M |
June 30, 2013 | 19.41M |
March 31, 2013 | 14.11M |
December 31, 2012 | 12.66M |
September 30, 2012 | 11.46M |
June 30, 2012 | 10.28M |
March 31, 2012 | 10.79M |
December 31, 2011 | 11.52M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
197.80M
Minimum
Sep 2020
357.69M
Maximum
Mar 2024
247.84M
Average
229.65M
Median
SG&A Expense (TTM) Benchmarks
Cytokinetics Inc | 169.45M |
Amicus Therapeutics Inc | 289.34M |
Predictive Oncology Inc | 11.44M |
Agios Pharmaceuticals Inc | 122.55M |
Arcutis Biotherapeutics Inc | 197.02M |